2015 Annual Meeting: Asthma, Respiratory and Sleep Disorders On Demand

You can earn up to 12.5 AMA PRA Category 1 Credit(s). This activity has also been designated by the ABAI for 5.5 MOC Part II Self-Assessment credits. Cost: $249 $125 for College Members, $375 $189 for non-members.

This package of courses includes the following asthma, respiratory and sleep disorder related sessions from the 2015 ACAAI Annual Meeting in San Antonio:

  • Biologics in Practice:  Unique Opportunity for Allergist Expertise (plenary session, MOC)
  • Updates in Severe Asthma (plenary session, MOC)
  • Asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS) (symposium)
  • Treatment Strategies for Children Having Both Persistent Allergic Rhinitis and Asthma (symposium)
  • Severe Asthma: Persistent Challenges; New Therapies (symposium)
  • Severe Asthma (workshop session, MOC)

Release Date: 12/15/2015
Expiration Date: 12/14/2018

Accreditation

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 12.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Learning Objectives

• Discuss phenotypes and endotypes in the context of the patient with severe asthma 
• Describe the relative advantages and disadvantages associated with various asthma pharmacotherapies, particularly biologics 
• Discuss the side effect profiles of the various new therapies and how to go about handling such complications

• Recognize how basic science research has identified distinct pathophysiological endotypes in severe asthma 
• Utilize appropriate biomarkers to categorize the endotype of a severe asthma patient in the allergy/immunology clinic 
• Design a management plan that is individualized to a severe asthma patient's particular phenotype and endotype

• Recognize that asthma, like COPD, can be an irreversible lung disease in both children and adults and be able to institute appropriate measures to slow this decline  
• Manage exacerbations in patients with asthma/COPD overlap syndrome (ACOS), and assess when, and if, such patients should be referred to another specialist for further care
• Discuss the comorbidities that occur in patients with asthma/COPD overlap syndrome (ACOS) and  be able to manage them

• Discuss which daily mono and combined medications and immunotherapy options are most effecitve in the pediatric population for persistent allergic rhinitis; explain what works for chronic sinusitis in the pediatric population; and debate if treatment should be different for children with or without concurrent asthma
• List the reasons that support, or lack therof, for the use of small particle size inhaled steroids in pediatric asthma; discuss the merits of nebulized vs. MDI vs. dry powder use of inhaled steroids in the pediatric patient (age 6 and older); and debate daily vs. dynamic dosing for pediatric asthmatics with "persistent" but not daily asthma symptoms
• Discuss overall safety of nasal and inhaled steroids in pediatrics; list the nasal and inhaled steroids with the best safety profile for pediatric patients; explain the published data and expert opinion on the safety of using both products confurrently in pediatric patients; and compare the safety of daily inhaled steroids over intermittent oral burst of steroids (e.g., 1-2 times/year) over a 1 to 2 year time period

• Summarize  the leading hypotheses regarding mechanisms for why severe asthma is treatment resistant 
• Discuss which patients will be appropriate candidates for new severe asthma therapies
• Discuss how to obtain new asthma therapies for their patients

• Describe how severe asthmatics are uniquely different and review the evaluation/assessment of these patients, comparing pediatric and adult and develop a treatment plan for patients with severe asthma

Additional information
Disclosure: 

Rohit K. Katial, MD, FACAAI -- Consultant/Advisor: AstraZeneca, GlaxoSmithKline, Meda, Teva; Speaker: GlaxoSmithKline, Meda

James L. Sublett, MD, FACAAI -- Consultant/Advisor: AllergyZone, Boston Scientific, Greer; Speaker: Genentech, GlaxoSmithKline, Meda, Merck, Sunovion, Teva; Supported/Contracted Research: Array BioPharma, AstraZeneca, Boehringer Ingelheim, Forest, Mylan, Sanofi

Larry Borish, MD, FACAAI -- Consultant/Advisor: Allakos, Knopp, Novartis, PluriStem

Thomas B. Casale, MD, FACAAI -- Consultant/Advisor: AstraZeneca, Genentech, Novartis, Sanofi, Teva

David A. Khan, MD, FACAAI -- Speaker: Baxter, Genentech

Stephen P. Peters, MD, PhD -- Consultant/Advisor: AstraZeneca, Boehringer Ingelheim, CSL Behring, Gilead, Merck, Novartis, Pfizer, Teva, PPD Development, Quintiles, Theron

Bradley E. Chipps, MD, FACAAI -- Consultant/Advisor: AstraZeneca, Boehringer Ingelheim, Genentech, Merck, Novartis; Speaker: AstraZeneca, Boehringer Ingelheim, Genentech, Merck, Novartis; Supported/Contracted Research: Stallergenes

Reynold A. Panettieri, MD -- Consultant/Advisor: AstraZeneca, Johnson & Johnson; Supported/Contracted Research: Gilead, Johnson & Johnson, Merck, Roche, Sanofi

Stephen P. Peters, MD, PhD -- Consultant/Advisor: AstraZeneca, Boehringer Ingelheim, CSL Behring, Gilead, Merck, Novartis, Pfizer, Teva, PPD Development, Quintiles, Theron

Nicola A. Hanania, MBBS -- Consultant/Advisor: AstraZeneca, Meda, Novartis, Pfizer, Roche, Sunovion; Speaker: Genentech; Supported/Contracted Research: Boehringer Ingelheim, Chiesi, Genentech, GlaxoSmithKline, Mylan, Novartis, Pfizer, Roche, Sunovion

Eli O. Meltzer, MD, FACAAI -- Consultant/Advisor: AstraZeneca, Boehringer Ingelheim, Circassia, GlaxoSmithKline, Greer, Johnson & Johnson, McNeill, Meda, Merck, Regeneron, Sanofi, Sunovion, Teva, Takeda, Valeant; Speaker: Alcon, Greer, Meda, Mylan, Sunovion, Teva, Takeda

Bobby Q. Lanier, MD, FACAAI -- Supported/Contracted Research: Merck, Novartis, Teva; Speaker: Genentech, Merck

John J. Oppenheimer, MD, FACAAI -- Consultant/Advisor: GlaxoSmithKline, Meda, Mylan; Supported/Contracted Research: AstraZeneca, MedImmune, Novartis

Leonard B. Bacharier, MD, FACAAI -- Consultant/Advisor: Boehringer Ingelheim, DBV Technologies, GlaxoSmithKline, Meda,Teva; Speaker: AstraZeneca, Novartis 

The following have no financial relationships to disclose:

Gerald B. Lee, MD

Elliot Israel, MD

David I. Bernstein, MD, FACAAI

Dana V. Wallace, MD, FACAAI

David P. Skoner, MD, FACAAI

Michael B. Foggs, MD, FACAAI

Kevin R. Murphy, MD, FACAAI (SC)

Course summary
Available credit: 
  • 12.50 AMA PRA Category 1 Credit™
  • 12.50 Attendance
  • 5.50 MOC
Course opens: 
12/15/2015
Course expires: 
12/14/2018
Cost:
$189.00
Rating: 
0

Available Credit

  • 12.50 AMA PRA Category 1 Credit™
  • 12.50 Attendance
  • 5.50 MOC

Accreditation Period

Course opens: 
12/15/2015
Course expires: 
12/14/2018

Price

Cost:
$189.00
Please login or create an account to take this course.